BDBM50241180 (6S,12S,15S)-1,6-diamino-12-(carboxymethyl)-16-hydroxy-1-imino-7,10,13-trioxo-2,8,11,14-tetraazahexadecane-15-carboxylic acid::(S)-3-[2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-((R)-1-carboxy-2-hydroxy-ethyl)-succinamic acid::(S)-3-[2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-((S)-1-carboxy-2-hydroxy-ethyl)-succinamic acid::2-[1-[1-amino-4-amino(imino)methylamino-(1S)-butylcarboxamidomethylcarboxamido]-2-carboxy-(1S)-ethylcarboxamido]-3-hydroxy-(2S)-propanoic acid::2-{1-[1-amino-4-amino(imino)methylaminobutylcarboxamidomethylcarboxamido]-2-carboxyethylcarboxamido}-3-hydroxypropanoic acid::3-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-(1-carboxy-2-hydroxy-ethyl)-succinamic acid::3-[2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-((S)-1-carboxy-2-hydroxy-ethyl)-succinamic acid::3-[2-(2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-(1-carboxy-2-hydroxy-ethyl)-succinamic acid::3-[2-(2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-(1-carboxy-2-hydroxy-ethyl)-succinamic acid (RGDS)::CHEMBL265628::RGDS
SMILES [#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](/[#7])-[#7])-[#6](=O)-[#7]-[#6]-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6](-[#8])=O)-[#6](=O)-[#7]-[#6@@H](-[#6]-[#8])-[#6](-[#8])=O
InChI Key InChIKey=CDETVRBIIZGKRO-UHFFFAOYSA-N
Data 24 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 24 hits for monomerid = 50241180
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of arachidonic acid-induced platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-3/beta-3(Human)
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Antagonist activity at FITC-tagged alpha3beta3 integrin in human platelet assessed as reduction of ADP-induced platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-3/beta-3(Human)
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
Affinity DataIC50: 3.10E+4nMAssay Description:Antagonist activity at FITC-tagged alpha3beta3 integrin in human platelet rich plasmaMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 5.10E+3nMAssay Description:Antagonist activity at GP2b/3a receptor (unknown origin) assessed as inhibition of interaction with fibrinogen after 2 hrs by ELISAMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of ADP-mediated platelet aggregation in human gel-filtered plateletsMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of fibrinogen binding to glycoprotein alpha IIb beta-3 integrin of activated plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+3nMAssay Description:Inhibition of fibronectin (GST-3Fn8-11) binding to recombinant soluble mini integrin alpha5-beta1More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.60E+4nMAssay Description:In vitro inhibition of ADP-mediated human gel filtered platelet aggregation.More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 7.50E+4nMAssay Description:Inhibition of ADP-induced human platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 9.50E+4nMAssay Description:Inhibition of human platelet adhesion to fibrinogenMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.45E+4nMAssay Description:Inhibition of platelet glycoprotein alpha IIb beta-3 integrin in ELISAMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 5.50E+4nMAssay Description:Inhibition of integrin alphaIIb-beta3 bindingMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of FITC-labeled fibrinogen binding to integrin alpha2bbeta3 receptor in human platelets by flow cytometryMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.64E+4nMAssay Description:Inhibition of collagen-induced platelet aggregationMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 7.90E+3nMAssay Description:Inhibition of [125I]fibrinogen binding to human Fibrinogen Receptor.More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 9.60E+3nMAssay Description:Inhibition of 125I-fibrinogen binding to alpha IIb beta-3 integrin as inhibition of activated plateletsMore data for this Ligand-Target Pair
TargetIntegrin alpha-2/beta-3(Human)
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Displacement of FITC-labeled fibrinogen from alpha2beta3 in human plateletsMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 6.20E+4nMAssay Description:Concentration required to inhibit adenosine diphosphate (ADP) induced aggregation of human platelets by 50% in vitro.More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 3.70E+5nMAssay Description:Concentration required to inhibit adenosine diphosphate (ADP) induced aggregation of guinea pig platelets by 50% in vitroMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.50E+5nMAssay Description:Inhibition of HUVEC adhesion to fibrinogen-coated platesMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 3.50E+3nMAssay Description:Inhibition of HUVEC adhesion to fibrinogen-coated platesMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.27E+4nMAssay Description:Inhibition of HUVEC adhesion to fibrinogen-coated platesMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 8.20E+4nMAssay Description:Ability to inhibit the aggregation of fixed human plateletsMore data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Human)
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
R. W. Johnson Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 180nMAssay Description:Ability to inhibit binding of biotin-labeled human fibrinogen to immobilized fibrinogen receptor purified from human erythroleukemia (HEL) cells.More data for this Ligand-Target Pair